(Total Views: 511)
Posted On: 11/22/2025 12:56:08 AM
Post# of 158777
Re: chazzledazzle #158602
Exactly,
We preparing the protocol ( protocols are for a trials , this is why they said we will talk with FDA about it ) if any patient remain stable can continue LL treatment beyond 48 weeks...
--" If any patient remain stable " .... well , maybe none will beyond 48 weeks ...
So read below again ..
With that in mind, we have prepared a rollover protocol to ensure that CRC patients who remain stable can continue leronlimab treatment beyond 48 weeks and to allow patients with disease progression the opportunity to receive leronlimab at a dose of 700 mg in combination with an ICI.
We preparing the protocol ( protocols are for a trials , this is why they said we will talk with FDA about it ) if any patient remain stable can continue LL treatment beyond 48 weeks...
--" If any patient remain stable " .... well , maybe none will beyond 48 weeks ...
So read below again ..
With that in mind, we have prepared a rollover protocol to ensure that CRC patients who remain stable can continue leronlimab treatment beyond 48 weeks and to allow patients with disease progression the opportunity to receive leronlimab at a dose of 700 mg in combination with an ICI.
(2)
(0)
